Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Clinical trial NCT03933956 · TERMINATED
Trial details
- NCT number
- NCT03933956
- Sponsor
- Singapore General Hospital
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-09
- Primary completion
- 2020-08-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.